Floatz logo

pf-08653944

Obesity

PfizerPhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
59/ 100

Competitive context

574 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

pf-08653944 is also rated in:

obesity disorderDormant
B
Indicative ·
60 / 100
View asset →
overnutritionDormant
CCC
Indicative ·
53 / 100
View asset →
nutritional deficiency diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →